M. Todd

发表

Quantification of the effect of clopidogrel on enzymatic infarct size related to a percutaneous coronary intervention in patients with acute coronary syndromes: insights from the CHAMPION percutaneous coronary intervention trial

Deepak L. Bhatt, H. White, G. Stone, 2013, Coronary artery disease.

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

Deepak L. Bhatt, M. Price, H. White, 2012, American heart journal.

Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention.

C. Grines, D. Kereiakes, B. Brodie, 2001, The Journal of invasive cardiology.

Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.

M. Price, M. Hutyra, D. Holmes, 2015, The heart surgery forum.

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX

Deepak L. Bhatt, M. Price, H. White, 2015, European heart journal.

Impact of intraprocedural stent thrombosis during percutaneous coronary intervention: insights from the CHAMPION PHOENIX Trial (Clinical Trial Comparing Cangrelor to Clopidogrel Standard of Care Therapy in Subjects Who Require Percutaneous Coronary Intervention).

Deepak L. Bhatt, M. Price, H. White, 2014, Journal of the American College of Cardiology.

Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experience

Deepak L. Bhatt, M. Price, H. White, 2018, European heart journal. Acute cardiovascular care.

SAT0203 Optimization of biologic tapering using ultrasound in ra patients

M. Todd, J. France, S. Bawa, 2018, Saturday, 16 JUNE 2018.

Effect of platelet inhibition with cangrelor during PCI on ischemic events.

Gregg W Stone, Matthew J Price, Deepak L. Bhatt, 2013, The New England journal of medicine.

A mutation in the methylenetetrahydrofolate reductase gene is not associated with increased risk for coronary artery disease or myocardial infarction.

J. Carlquist, T. Bair, M. Todd, 1997, Journal of the American College of Cardiology.

Rationale and design of the Cangrelor versus standard therapy to acHieve optimal Management of Platelet InhibitiON PHOENIX trial.

Deepak L. Bhatt, M. Price, H. White, 2012, American heart journal.

Safety and efficacy of cangrelor, an intravenous, short-acting platelet inhibitor in patients requiring coronary artery bypass surgery.

M. Price, M. Hutyra, D. Holmes, 2015, The heart surgery forum.